Screener
Solid Biosciences Inc. SLDB Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,360 | $3,224 |
| Accrued expenses and other current liabilities | 17,790 | 18,945 |
| Operating lease liabilities, current | 2,234 | 2,103 |
| Derivative liabilities | 4,200 | 9,200 |
| Total current liabilities | 28,584 | 33,472 |
| Non-current liabilities: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s accrued expenses?
- Solid Biosciences Inc. (SLDB) reported accrued expenses of $17.79M in Q2 2026.
- How has Solid Biosciences Inc.'s accrued expenses changed year-over-year?
- Solid Biosciences Inc.'s accrued expenses increased by 7.5% year-over-year, from $16.55M to $17.79M.
- What is the long-term trend for Solid Biosciences Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Solid Biosciences Inc.'s accrued expenses has grown at a 17.0% compound annual growth rate (CAGR), from $8.64M to $18.95M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Solid Biosciences Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude